利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。

Objectives: 1. Discuss the difference between Europe and the US when it comes to the dermal filler market.
2. Review what is going on in the US, where things stand, and what we can hope for in the near to not too distant future.

Introduction: One major difference between Europe and the US when it comes to the dermal filler market, is that in Europe, there are many fillers and filler companies bringing a myriad of products to our colleagues, which allows them great variety when it comes to using them for wrinkle reduction or for volumization.

Results: This is in stark contrast to the US, where we have a limited number of dermal fillers, due to a more stringent approval process by the US FDA and by the higher costs of running the clinical trials needed to bring a filler to the market. Several new fillers have recently been or will be approved and several more are primed to begin US clinical trials looking for approval when those trials are complete.

Conclusion: This presentation will review what is going on in the US, where things stand, and what we can hope for in the near to not too distant future.

利益冲突声明

您有否接受任何资金来支持研究这个主题？
是
请注明名称（个人，公司，学会等等）: Allergan, Galderma, Merz Aesthetic, Prollenium, Croma

您是否接受过关于这项研究的任何酬金或其他报酬？
是
请注明名称（个人，公司，学会等等）: Allergan, Galderma, Merz Aesthetic, Prollenium, Croma

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作的完成感谢以下机构的支持： Allergan, Galderma, Merz Aesthetic, Prollenium, Croma

利益冲突声明

您有否接受任何资金来支持研究这个主题？
否

您是否接受过关于这项研究的任何酬金或其他报酬？
否

你是否和任何与您的研究所涉及的药物，材料或工具有密切联系的实体存在财务关系？
否

你是否拥有或者您已经为您此研究中的工具，药物或材料申请任何专利？
否

这项工作没有任何直接或间接的资金支持。由作者自己承担责任。